Sujay Kango - 30 Mar 2022 Form 4 Insider Report for INFINITY PHARMACEUTICALS, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 30 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Mar 2022, 19:08:25 UTC
Prior SEC filing: 23 Nov 2021
Next SEC filing: 07 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Seth A. Tasker, attorney-in-fact

Key filing fact

Sujay Kango filed Form 4 for INFINITY PHARMACEUTICALS, INC. on 31 Mar 2022.

Key facts

This page summarizes Sujay Kango's Form 4 filing for INFINITY PHARMACEUTICALS, INC..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 31 Mar 2022, 19:08.

Change

Previous filing in this sequence was filed on 23 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INFI transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +90,000
Change %
Price: $0.000000
Shares after: 90,000
Date: 30 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 90,000
Exercise price: $1.13
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 1/8th of the total number of shares on March 31, 2022 and as to 1/8th of the total number of shares at the end of each calendar quarter thereafter, provided that the Reporting Person continues to serve as a Director of the Issuer.